Astemizole
SIGMA/A2861 - ≥98% (HPLC)
Synonym: 1-
CAS Number: 68844-77-9
Empirical Formula (Hill Notation): C28H31FN4O
Molecular Weight: 458.57
EC Number: 272-441-9
MDL Number: MFCD00153919
Linear Formula: C28H31FN4O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | powder |
| InChI | 1S/C28H31FN4O/c1-34-25-12 |
| InChI key | GXDALQBWZGODGZ-UHFFFAOYSA |
| originator | Johnson & Johnson |
| Quality Level | 100  |
| SMILES string | COc1ccc(CCN2CCC(CC2)Nc3nc |
| solubility | DMSO: >20 mg/mL |
| storage condition | desiccated |
| protect from light | |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Astermizole is a potent hERG potassium channel blocker (IC50 of 0.9 nM) and may used as a pharmacological chaperone to correct folding defects and restore protein function for some mutated forms of hERG channels. It has also been studied for treatment of malaria, hERG and hEAG channel function in cancer and as a second generation antihistamine H-1 antagonist. |
| Features and Benefits: | This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Johnson & Johnson . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |